

Finn Gustafsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8207492/publications.pdf>

Version: 2024-02-01

241
papers

14,169
citations

71102

41
h-index

25787

108
g-index

246
all docs

246
docs citations

246
times ranked

10482
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
2	Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. New England Journal of Medicine, 2016, 375, 1221-1230.	27.0	1,350
3	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	7.1	820
4	Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 1505-1535.	7.1	555
5	2019 EACTS Expert Consensus on long-term mechanical circulatory support. European Journal of Cardio-thoracic Surgery, 2019, 56, 230-270.	1.4	255
6	A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE) Tj ETQq0 0 0 rgBT /Overlock 10 TF 5	13.7	238
7	Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes. European Journal of Heart Failure, 2017, 19, 595-602.	7.1	228
8	Incidence of cancer in patients with chronic heart failure: a long-term follow-up study. European Journal of Heart Failure, 2016, 18, 260-266.	7.1	158
9	Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nature Reviews Cardiology, 2020, 17, 641-655.	13.7	143
10	An ISHLT consensus document for prevention and management strategies for mechanical circulatory support infection. Journal of Heart and Lung Transplantation, 2017, 36, 1137-1153.	0.6	142
11	Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure. Circulation, 2017, 136, 1772-1780.	1.6	134
12	The European Registry for Patients with Mechanical Circulatory Support (EUROMACS) of the European Association for Cardio-Thoracic Surgery (EACTS): second report. European Journal of Cardio-thoracic Surgery, 2018, 53, 309-316.	1.4	121
13	Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE) Tj ETQq1 1 0.784314 rgBT /Overlock 112	13.7	112
14	Effects of an Interatrial Shunt on Rest and Exercise Hemodynamics: Results of a Computer Simulation in Heart Failure. Journal of Cardiac Failure, 2014, 20, 212-221.	1.7	111
15	Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study. PLoS ONE, 2016, 11, e0161208.	2.5	108
16	The Influence of Age on Hemodynamic Parameters During Rest and Exercise in Healthy Individuals. JACC: Heart Failure, 2017, 5, 337-346.	4.1	108
17	The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. European Heart Journal, 2021, 42, 1621-1631.	2.2	102
18	Exercise in heart failure patients supported with a left ventricular assist device. Journal of Heart and Lung Transplantation, 2015, 34, 489-496.	0.6	101

#	ARTICLE	IF	CITATIONS
19	Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 836.	6.1	95
20	Heart failure clinics and outpatient management: review of the evidence and call for quality assurance. <i>European Heart Journal</i> , 2004, 25, 1596-1604.	2.2	86
21	Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 106-116.	11.4	80
22	Association of Carpal Tunnel Syndrome With Amyloidosis, Heart Failure, and Adverse Cardiovascular Outcomes. <i>Journal of the American College of Cardiology</i> , 2019, 74, 15-23.	2.8	77
23	Effect of increasing pump speed during exercise on peak oxygen uptake in heart failure patients supported with a continuous-flow left ventricular assist device. A double-blind randomized study. <i>European Journal of Heart Failure</i> , 2014, 16, 403-408.	7.1	74
24	Pulmonary artery pulsatility index: physiological basis and clinical application. <i>European Journal of Heart Failure</i> , 2020, 22, 32-38.	7.1	72
25	Effects of Interatrial Shunt on Pulmonary Vascular Function in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2539-2550.	2.8	69
26	Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. <i>Circulation</i> , 2021, 143, 1852-1862.	1.6	65
27	Peripartum cardiomyopathy in Denmark: a retrospective, population-based study of incidence, management and outcome. <i>European Journal of Heart Failure</i> , 2017, 19, 1712-1720.	7.1	64
28	Effect of age on short and long-term mortality in patients admitted to hospital with congestive heart failure. <i>European Heart Journal</i> , 2004, 25, 1711-1717.	2.2	62
29	Six-month outcomes after treatment of advanced heart failure with a full magnetically levitated continuous flow left ventricular assist device: report from the ELEVATE registry. <i>European Heart Journal</i> , 2018, 39, 3454-3460.	2.2	62
30	Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial. <i>American Heart Journal</i> , 2020, 228, 47-56.	2.7	61
31	Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis. <i>Journal of the American College of Cardiology</i> , 2020, 76, 767-777.	2.8	61
32	Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2740-2751.	2.8	57
33	Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure. <i>Circulation</i> , 2022, 145, 1592-1604.	1.6	54
34	The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT3 trial. <i>European Journal of Heart Failure</i> , 2017, 19, 566-575.	7.1	53
35	Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2018, 5, 685-694.	3.1	53
36	Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort. <i>European Journal of Heart Failure</i> , 2020, 22, 1777-1785.	7.1	53

#	ARTICLE	IF	CITATIONS
37	Effect of moderate- versus high-intensity exercise on vascular function, biomarkers and quality of life in heart transplant recipients: A randomized, crossover trial. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1033-1041.	0.6	52
38	Increased blood pressure and aortic stiffness among abusers of anabolic androgenic steroids. <i>Journal of Hypertension</i> , 2018, 36, 277-285.	0.5	49
39	Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE Registry. <i>European Heart Journal</i> , 2020, 41, 3801-3809.	2.2	49
40	Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1226-1237.	7.1	47
41	Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. <i>ESC Heart Failure</i> , 2019, 6, 62-69.	3.1	45
42	Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period. <i>ESC Heart Failure</i> , 2019, 6, 174-181.	3.1	43
43	A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. <i>International Journal of Cardiology</i> , 2019, 297, 83-90.	1.7	42
44	Urinary Proteomics Pilot Study for Biomarker Discovery and Diagnosis in Heart Failure with Reduced Ejection Fraction. <i>PLoS ONE</i> , 2016, 11, e0157167.	2.5	42
45	Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 715-722.	7.1	41
46	Cardiac systolic dysfunction in past illicit users of anabolic androgenic steroids. <i>American Heart Journal</i> , 2018, 203, 49-56.	2.7	40
47	Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial. <i>Transplant International</i> , 2016, 29, 819-829.	1.6	39
48	Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients. <i>Circulation: Heart Failure</i> , 2018, 11, e004050.	3.9	39
49	Pump speed modulations and sub-maximal exercise tolerance in left ventricular assist device recipients: A double-blind, randomized trial. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 36-41.	0.6	38
50	Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). <i>Trials</i> , 2019, 20, 374.	1.6	35
51	Treatment with beta-blockers in nurse-led heart failure clinics: Titration efficacy and predictors of failure. <i>European Journal of Heart Failure</i> , 2007, 9, 910-916.	7.1	34
52	Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1690-1697.	7.1	34
53	Nationwide trends in development of heart failure and mortality after first-time myocardial infarction 1997-2010: A Danish cohort study. <i>European Journal of Internal Medicine</i> , 2014, 25, 731-738.	2.2	33
54	Insulin sensitivity in relation to fat distribution and plasma adipocytokines among abusers of anabolic androgenic steroids. <i>Clinical Endocrinology</i> , 2017, 87, 249-256.	2.4	33

#	ARTICLE	IF	CITATIONS
55	Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 321-332.	4.1	33
56	<scp>COVID</scp>â€19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1806-1818.	7.1	32
57	Clinical outcome of transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel implant. <i>International Journal of Cardiology</i> , 2015, 187, 227-228.	1.7	30
58	Screening for heart transplantation and left ventricular assist system: results from the ScrEEning for advanced Heart Failure treatment (SEEâ€CHF) study. <i>European Journal of Heart Failure</i> , 2018, 20, 152-160.	7.1	29
59	Cardiac remodellingâ€Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 927-943.	7.1	29
60	The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1569-1580.	2.5	28
61	Long-Term Follow-Up of DANISH (The Danish Study to Assess the Efficacy of ICDs in Patients With) Tj ETQq1 1 0.784314 rgBTJ /Overlock	1.6	28
62	Exercise Intolerance in Heart Failure: Did We Forget the Brain?. <i>Canadian Journal of Cardiology</i> , 2016, 32, 475-484.	1.7	26
63	Advanced heart failure: guidelineâ€directed medical therapy, diuretics, inotropes, and palliative care. <i>ESC Heart Failure</i> , 2022, 9, 1507-1523.	3.1	26
64	Heart transplantation in arrhythmogenic right ventricular cardiomyopathy â€ Experience from the Nordic ARVC Registry. <i>International Journal of Cardiology</i> , 2018, 250, 201-206.	1.7	25
65	Pulmonary Arterial Wedge Pressure at Rest and During Exercise in Healthy Adults: A Systematic Review and Meta-analysis. <i>Journal of Cardiac Failure</i> , 2019, 25, 114-122.	1.7	25
66	Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study. <i>Transplantation</i> , 2020, 104, 154-164.	1.0	25
67	Cardiomyocyte Expression and Cell-specific Processing of Procholecystokinin. <i>Journal of Biological Chemistry</i> , 2015, 290, 6837-6843.	3.4	24
68	Pulmonary hypertension as a risk factor of mortality after lung transplantation. <i>Clinical Transplantation</i> , 2016, 30, 357-364.	1.6	24
69	Peripartum cardiomyopathy: a systematic literature review. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2016, 95, 1205-1219.	2.8	23
70	Ramp Study Hemodynamics, Functional Capacity, and Outcome in Heart Failure Patients with Continuous-Flow Left Ventricular Assist Devices. <i>ASAIO Journal</i> , 2016, 62, 442-446.	1.6	23
71	Repetitive levosimendan treatment in the management of advanced heart failure. <i>European Heart Journal Supplements</i> , 2018, 20, I11-I20.	0.1	23
72	Impact of Baseline Hemodynamics on the Effects of a Transcatheter Interatrial Shunt Device in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018, 11, e004540.	3.9	23

#	ARTICLE	IF	CITATIONS
73	Severe loss of right ventricular longitudinal contraction occurs after cardiopulmonary bypass in patients with preserved right ventricular output. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1661-1670.	1.5	23
74	Evaluation of an electronic, patient-focused management system aimed at preventing cytomegalovirus disease following solid organ transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13252.	1.7	23
75	Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies. <i>European Heart Journal</i> , 2022, 43, 2237-2246.	2.2	23
76	Outcome after heart-lung or lung transplantation in patients with Eisenmenger syndrome. <i>Heart</i> , 2020, 106, 127-132.	2.9	22
77	Cardiac remodelling—Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 944-958.	7.1	22
78	False-positive defects in technetium-99m sestamibi myocardial single-photon emission tomography in healthy athletes with left ventricular hypertrophy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 1308-1312.	6.4	21
79	Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 117.	1.7	21
80	Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz215.	0.9	21
81	The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). <i>American Heart Journal</i> , 2021, 231, 137-146.	2.7	21
82	Outcomes following SARS-CoV-2 infection in individuals with and without solid organ transplantation—A Danish nationwide cohort study. <i>American Journal of Transplantation</i> , 2022, 22, 2627-2636.	4.7	21
83	Iron deficiency: Prevalence and relation to cardiovascular biomarkers in heart failure outpatients. <i>International Journal of Cardiology</i> , 2015, 195, 143-148.	1.7	20
84	Copeptin in Heart Failure. <i>Advances in Clinical Chemistry</i> , 2016, 73, 29-64.	3.7	20
85	Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary. <i>European Journal of Heart Failure</i> , 2021, 23, 1597-1609.	7.1	20
86	Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry. <i>European Journal of Heart Failure</i> , 2021, 23, 2058-2069.	7.1	20
87	Two Decades of Cardiac Amyloidosis. <i>JACC: CardioOncology</i> , 2021, 3, 522-533.	4.0	20
88	Prognostic Value of Peak Oxygen Uptake in Patients Supported With Left Ventricular Assist Devices (PRO-VAD). <i>JACC: Heart Failure</i> , 2021, 9, 758-767.	4.1	20
89	The inodilator levosimendan as a treatment for acute heart failure in various settings. <i>European Heart Journal Supplements</i> , 2017, 19, C2-C7.	0.1	19
90	Postmarket Experience With HeartMate 3 Left Ventricular Assist Device: 30-Day Outcomes From the ELEVATE Registry. <i>Annals of Thoracic Surgery</i> , 2019, 107, 33-39.	1.3	19

#	ARTICLE	IF	CITATIONS
91	Impact of Interatrial Shunts on Invasive Hemodynamics and Exercise Tolerance in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2020, 9, e016760.	3.7	19
92	Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 754-764.	7.1	19
93	Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden. <i>Open Heart</i> , 2021, 8, e001755.	2.3	19
94	Incidence and predictors of hospitalization or death in patients managed in multidisciplinary heart failure clinics. <i>European Journal of Heart Failure</i> , 2009, 11, 413-419.	7.1	18
95	Right ventricular dysfunction after cardiac surgery – diagnostic options. <i>Scandinavian Cardiovascular Journal</i> , 2017, 51, 114-121.	1.2	18
96	Sacubitril/Valsartan Augments Postprandial Plasma Concentrations of Active GLP-1 When Combined With Sitagliptin in Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3868-3876.	3.6	18
97	Alcohol Intake in Patients With Cardiomyopathy and Heart Failure: Consensus and Controversy. <i>Circulation: Heart Failure</i> , 2022, 15, 101161CIRCHEARTFAILURE121009459.	3.9	18
98	Measures of right ventricular function after transcatheter versus surgical aortic valve replacement. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2017, 24, iw350.	1.1	17
99	Incidence Rates and Risk Factors of <i>Clostridioides difficile</i> Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz086.	0.9	17
100	Identification of Patients with New-Onset Heart Failure and Reduced Ejection Fraction in Danish Administrative Registers. <i>Clinical Epidemiology</i> , 2020, Volume 12, 589-594.	3.0	17
101	Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 233-241.	1.7	17
102	Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	3.9	17
103	Left Ventricular Assist Devices at the Crossroad of Innovation in Advanced Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 1291-1294.	1.7	16
104	Lung diffusion capacity in advanced heart failure: relation to central haemodynamics and outcome. <i>ESC Heart Failure</i> , 2019, 6, 379-387.	3.1	15
105	Cholesterol lowering with EVOlocumab to prevent cardiac allograft Vasculopathy in De novo heart transplant recipients: Design of the randomized controlled EVOLVD trial. <i>Clinical Transplantation</i> , 2020, 34, e13984.	1.6	15
106	Classification of death causes after transplantation (CLASS). <i>Medicine (United States)</i> , 2018, 97, e11564.	1.0	14
107	Host Genetics and Antiviral Immune Responses in Adult Patients With Multisystem Inflammatory Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 718744.	4.8	14
108	Effect of everolimus initiation and early calcineurin inhibitor withdrawal on myocardial FOXP3 + regulatory T cells in heart transplantation. <i>Transplant Immunology</i> , 2016, 38, 75-77.	1.2	13

#	ARTICLE	IF	CITATIONS
109	Design and rationale of the HITS randomized controlled trial: Effect of High-intensity Interval Training in de novo Heart Transplant Recipients in Scandinavia. <i>American Heart Journal</i> , 2016, 172, 96-105.	2.7	13
110	Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial). <i>American Journal of Cardiology</i> , 2019, 124, 1912-1917.	1.6	13
111	Right Ventricular and Pulmonary Vascular Function are Influenced by Age and Volume Expansion in Healthy Humans. <i>Journal of Cardiac Failure</i> , 2019, 25, 51-59.	1.7	13
112	Biomarkers and Their Relation to Cardiac Function Late After Peripartum Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2021, 27, 168-175.	1.7	13
113	How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?. <i>Journal of Hypertension</i> , 2010, 28, 1595-1598.	0.5	12
114	Maximizing scientific knowledge from randomized clinical trials. <i>American Heart Journal</i> , 2010, 159, 937-943.	2.7	12
115	Relationships Between Biomarkers and Left Ventricular Filling Pressures at Rest and During Exercise in Patients After Myocardial Infarction. <i>Journal of Cardiac Failure</i> , 2014, 20, 959-967.	1.7	12
116	Use of digoxin and risk of death or readmission for heart failure and sinus rhythm: A nationwide propensity score matched study. <i>International Journal of Cardiology</i> , 2016, 221, 944-950.	1.7	12
117	Impact of CMV PCR Blips in Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation. <i>Transplantation Direct</i> , 2018, 4, e355.	1.6	12
118	Computed Tomographyâ€“Estimated Right Ventricular Function and Exercise Capacity in Patients with Continuous-Flow Left Ventricular Assist Devices. <i>ASAIO Journal</i> , 2020, 66, 8-16.	1.6	12
119	Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e020418.	3.7	12
120	Comprehensive Physiological Modeling Provides Novel Insights Into Heart Failure With Preserved Ejection Fraction Physiology. <i>Journal of the American Heart Association</i> , 2021, 10, e021584.	3.7	12
121	Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries. <i>ESC Heart Failure</i> , 2022, 9, 2528-2537.	3.1	12
122	Renal-sparing strategies in cardiac transplantation. <i>Current Opinion in Organ Transplantation</i> , 2009, 14, 566-570.	1.6	11
123	Low-Dose Aspirin in Heart Failure Notâ€“Complicatedâ€“by Atrial Fibrillation. <i>JACC: Heart Failure</i> , 2018, 6, 156-167.	4.1	11
124	Effect of Heart Rate Reserve on Exercise Capacity in Patients Treated with a Continuous Left Ventricular Assist Device. <i>ASAIO Journal</i> , 2020, 66, 160-165.	1.6	11
125	Risk Factors for Morbidity and Mortality Following Hospitalization for Pericarditis. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2623-2631.	2.8	11
126	Reduced Diuretic Dose in Patients Treated With Eplerenone. <i>Circulation: Heart Failure</i> , 2020, 13, e006597.	3.9	11

#	ARTICLE	IF	CITATIONS
127	Posttransplantation Diabetes Mellitus Among Solid Organ Recipients in a Danish Cohort. <i>Transplant International</i> , 2022, 35, 10352.	1.6	11
128	Wound complications and surgical events in de novo heart transplant patients treated with everolimus: Post-hoc analysis of the SCHEDULE trial. <i>International Journal of Cardiology</i> , 2016, 210, 80-84.	1.7	10
129	Early changes in left atrial volume after acute myocardial infarction. Relation to invasive hemodynamics at rest and during exercise. <i>International Journal of Cardiology</i> , 2016, 223, 717-722.	1.7	10
130	Immune function as predictor of infectious complications and clinical outcome in patients undergoing solid organ transplantation (the ImmuneMo:SOT study): a prospective non-interventional observational trial. <i>BMC Infectious Diseases</i> , 2019, 19, 573.	2.9	10
131	“Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation” <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3125-3135.	2.5	10
132	Prevalence of heart failure and other risk factors among first-degree relatives of women with peripartum cardiomyopathy. <i>Heart</i> , 2019, 105, 1057-1062.	2.9	10
133	The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trial. <i>Europace</i> , 2019, 21, 900-908.	1.7	10
134	Use of T Cell Mediated Immune Functional Assays for Adjustment of Immunosuppressive or Anti-infective Agents in Solid Organ Transplant Recipients: A Systematic Review. <i>Frontiers in Immunology</i> , 2020, 11, 567715.	4.8	10
135	Right ventricular transverse displacement increases following cardiac surgery: possibly compensating loss in tricuspid annular plane systolic excursion (TAPSE). <i>Journal of Clinical Monitoring and Computing</i> , 2020, 34, 1139-1148.	1.6	10
136	Bioactive adrenomedullin in plasma is associated with biventricular filling pressures in patients with advanced heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 489-491.	7.1	10
137	Socioeconomic Disparities in Referral for Invasive Hemodynamic Evaluation for Advanced Heart Failure: A Nationwide Cohort Study. <i>Circulation: Heart Failure</i> , 2021, 14, e008662.	3.9	10
138	HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge. <i>ESC Heart Failure</i> , 2021, 8, 4425-4443.	3.1	10
139	Management of patients with cardiogenic shock on temporary mechanical circulatory support: urgent transplantation or on to the next pump?. <i>European Journal of Heart Failure</i> , 2018, 20, 187-189.	7.1	10
140	Clinical features and determinants of VO_{2peak} in de novo heart transplant recipients. <i>World Journal of Transplantation</i> , 2018, 8, 188-197.	1.6	10
141	The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker). <i>Cardiovascular Diabetology</i> , 2022, 21, 34.	6.8	10
142	Vasopressin and Vasopressin Antagonists in Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2017, 243, 307-328.	1.8	9
143	Bromocriptine for the treatment of peripartum cardiomyopathy: comparison of outcome with a Danish cohort. <i>European Heart Journal</i> , 2018, 39, 3476-3477.	2.2	9
144	Performance of Prognostic Risk Scores in Heart Failure Patients: Do Sex Differences Exist?. <i>Canadian Journal of Cardiology</i> , 2020, 36, 45-53.	1.7	9

#	ARTICLE	IF	CITATIONS
145	Bacterial and fungal bloodstream infections in solid organ transplant recipients: results from a Danish cohort with nationwide follow-up. <i>Clinical Microbiology and Infection</i> , 2022, 28, 391-397.	6.0	9
146	Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2017-2026.	4.4	9
147	Pulmonary venous remodeling in COPDâ€pulmonary hypertension and idiopathic pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017, 7, 514-521.	1.7	8
148	Predictors of Physical Capacity 6 Months After Implantation of a Full Magnetically Levitated Left Ventricular Assist Device: An Analysis From the ELEVATE Registry. <i>Journal of Cardiac Failure</i> , 2020, 26, 580-587.	1.7	8
149	Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). <i>Circulation</i> , 2021, 143, 2208-2210.	1.6	8
150	Suspicion, screening, and diagnosis of wildâ€type transthyretin amyloid cardiomyopathy: a systematic literature review. <i>ESC Heart Failure</i> , 2022, 9, 1524-1541.	3.1	8
151	Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic artificial heart implantation. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1214-1217.	0.6	8
152	Cardiac procholecystokinin expression during haemodynamic changes in the mammalian heart. <i>Peptides</i> , 2018, 108, 7-13.	2.4	7
153	Intravascular ultrasoundâ€guided selection for early noninvasive cardiac allograft vasculopathy screening in heart transplant recipients. <i>Clinical Transplantation</i> , 2020, 34, e14124.	1.6	7
154	Measles, Mumps, Rubella, and Varicella Zoster Virus Serology and Infections in Solid Organ Transplant Recipients During the First Year Posttransplantation. <i>Clinical Infectious Diseases</i> , 2020, 73, e3733-e3739.	5.8	7
155	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist deviceâ€supported patients for the nonâ€left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. <i>ESC Heart Failure</i> , 2021, 8, 4409-4424.	3.1	7
156	Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction. <i>Drugs</i> , 2022, 82, 375-405.	10.9	7
157	Targeting the aldosterone pathway in cardiovascular disease. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 135-145.	1.9	6
158	Mitral regurgitation â€” Unmet need for improved management strategies. <i>IJC Heart and Vasculature</i> , 2014, 5, 26-41.	1.1	6
159	Influence of renal impairment on myocardial function in outpatients with systolic heart failure: An echocardiographic and cardiac biomarker study. <i>International Journal of Cardiology</i> , 2014, 177, 942-948.	1.7	6
160	Psychological adaptation after peripartum cardiomyopathy: A qualitative study. <i>Midwifery</i> , 2018, 62, 52-60.	2.3	6
161	Recessive Inheritance of a Rare Variant in the Nuclear Mitochondrial Gene for <i>AARS2</i> in Late-Onset Dilated Cardiomyopathy. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, 560-562.	3.6	6
162	Impact of Hypothermia on Oxygenation Variables and Metabolism in Survivors of Out-of-Hospital Cardiac Arrest Undergoing Targeted Temperature Management at 33Â°C Versus 36Â°C. <i>Therapeutic Hypothermia and Temperature Management</i> , 2021, 11, 170-178.	0.9	6

#	ARTICLE	IF	CITATIONS
163	Predicting 10-year mortality in older adults using VO2max, oxygen uptake efficiency slope and frailty class. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1148-1151.	1.8	6
164	Long-term prognosis following hospitalization for acute myocarditis – a matched nationwide cohort study. <i>Scandinavian Cardiovascular Journal</i> , 2021, 55, 264-269.	1.2	6
165	Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma. <i>Endocrine Connections</i> , 2020, 9, 438-444.	1.9	6
166	Determinants of Functional Capacity and Quality of Life After Implantation of a Durable Left Ventricular Assist Device. <i>Cardiac Failure Review</i> , 2020, 6, e29.	3.0	6
167	Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. <i>International Journal of Cardiovascular Imaging</i> , 2021, , 1.	1.5	6
168	Survival and adverse events in patients with atrial fibrillation at left ventricular assist device implantation: an analysis of the European Registry for Patients with Mechanical Circulatory Support. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 61, 1164-1175.	1.4	6
169	Education and certification on heart failure of the <sc>H</sc>eart <sc>F</sc>ailure <sc>A</sc>ssociation of the <sc>E</sc>uropean <sc>S</sc>ociety of <sc>C</sc>ardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 249-253.	7.1	6
170	Effect of influenza vaccination in solid organ transplant recipients: A nationwide population-based cohort study. <i>American Journal of Transplantation</i> , 2022, 22, 2409-2417.	4.7	6
171	Outcomes and hospital admissions during long-term support with a HeartMate II. <i>Scandinavian Cardiovascular Journal</i> , 2015, 49, 367-75.	1.2	6
172	The Influence of Diabetes Mellitus on Midregional Proadrenomedullin Concentrations and Prognostic Value in Heart Failure Outpatients. <i>Journal of Cardiac Failure</i> , 2015, 21, 250-257.	1.7	5
173	Continuous-flow LVADs in the Nordic countries: complications and mortality and its predictors. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 14-20.	1.2	5
174	Exercise Tolerance in Patients Treated With a Durable Left Ventricular Assist Device: Importance of Myocardial Recovery. <i>Journal of Cardiac Failure</i> , 2021, 27, 486-493.	1.7	5
175	An Observational Prospective Cohort Study of Incidence and Outcome of Streptococcus pneumoniae and Hemophilus influenzae Infections in Adult Solid Organ Transplant Recipients. <i>Microorganisms</i> , 2021, 9, 1371.	3.6	5
176	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. <i>ESC Heart Failure</i> , 2021, 8, 4394-4408.	3.1	5
177	Incidence and Impact of Parvovirus B19 Infection in Seronegative Solid Organ Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2021, 224, 865-869.	4.0	5
178	Circulating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men. <i>Clinical Chemistry</i> , 2022, 68, 713-720.	3.2	5
179	Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial. <i>Diabetes</i> , 2022, 71, 812-820.	0.6	5
180	Plasma NGAL and glomerular filtration rate in cardiac transplant recipients treated with standard or reduced calcineurin inhibitor levels. <i>Biomarkers in Medicine</i> , 2014, 8, 239-245.	1.4	4

#	ARTICLE	IF	CITATIONS
181	Influence of renal impairment on aldosterone status, calcium metabolism, and vasopressin activity in outpatients with systolic heart failure. <i>ESC Heart Failure</i> , 2017, 4, 554-562.	3.1	4
182	Hemodynamic effects of short-term infusion of a vasopressin V1A/V2 receptor antagonist conivaptan in patients with chronic heart failure during submaximal exercise. <i>American Heart Journal</i> , 2018, 203, 101-104.	2.7	4
183	Relationship between invasive hemodynamics and liver function in advanced heart failure. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 235-246.	1.2	4
184	Clinical presentation and outcomes in women and men with advanced heart failure. <i>Scandinavian Cardiovascular Journal</i> , 2020, 54, 361-368.	1.2	4
185	Is aspirin needed to prevent thrombotic events in patients treated with a HeartMate 3 left ventricular assist device?. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 526-528.	0.6	4
186	Tuberculosis among Patients Undergoing Solid Organ Transplantation or Dialysis in a Low-Endemic Country, 2004-2017. <i>Tuberculosis Research and Treatment</i> , 2020, 2020, 1-7.	0.6	4
187	Comparative analysis of regional outcomes and adverse events after continuous-flow left ventricular assist device implantation: An IMACS analysis. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 904-914.	0.6	4
188	The Effect of Common Interventions in the Intensive Care Unit on Right Ventricular Function After Cardiac Surgery—An Intervention Study. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020, 34, 1211-1219.	1.3	4
189	Mild acute cellular rejection and development of cardiac allograft vasculopathy assessed by intravascular ultrasound and coronary angiography in heart transplant recipients—a SCHEDULE trial substudy. <i>Transplant International</i> , 2020, 33, 517-528.	1.6	4
190	Prognostic value of myocardial flow reserve obtained by 82-rubidium positron emission tomography in long-term follow-up after heart transplantation. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 2555-2567.	2.1	4
191	Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 824-835.	4.1	4
192	Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next Generation Sequencing. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab462.	0.9	4
193	NT-proBNP and ICD in Nonischemic Systolic Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 161-171.	4.1	4
194	Oxygen Uptake During Activities of Daily Life in Patients Treated With a Left Ventricular Assist Device. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 982-990.	0.6	4
195	Healthcare resource use of patients with transthyretin amyloid cardiomyopathy. <i>ESC Heart Failure</i> , 2022, 9, 1636-1642.	3.1	4
196	Neurohormonal activation and exercise tolerance in patients supported with a continuous-flow left ventricular assist device. <i>International Journal of Cardiology</i> , 2016, 220, 196-200.	1.7	3
197	Layer-specific deformation analysis in severe aortic valve stenosis, primary mitral valve regurgitation, and healthy individuals validated against invasive hemodynamic measurements of heart function. <i>Echocardiography</i> , 2018, 35, 170-178.	0.9	3
198	Copeptin levels and invasive hemodynamics in patients with advanced heart failure. <i>Biomarkers in Medicine</i> , 2018, 12, 861-870.	1.4	3

#	ARTICLE	IF	CITATIONS
199	Catheter ablation and mortality, stroke and heart failure readmission with atrial fibrillation. <i>Open Heart</i> , 2020, 7, e001369.	2.3	3
200	Plasma Somatostatin in Advanced Heart Failure: Association with Cardiac Filling Pressures and Outcome. <i>Cardiology</i> , 2020, 145, 769-778.	1.4	3
201	The contribution of cardiac and extracardiac factors to NT-proBNP concentrations in patients with advanced heart failure before and after left ventricular assist device implantation. <i>Peptides</i> , 2021, 135, 170420.	2.4	3
202	Association between routine measures of graft function and mortality in heart transplant recipients. <i>Heart</i> , 2022, 108, 307-311.	2.9	3
203	Efficacy of the COVID-19 vaccine in heart transplant recipients: what we know and what we ignore. <i>European Journal of Heart Failure</i> , 2021, 23, 1560-1562.	7.1	3
204	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). <i>BMJ Open</i> , 2019, 9, e029098.	1.9	3
205	Rate of thromboembolic and bleeding events in patients undergoing concomitant aortic valve surgery with left ventricular assist device implantation. <i>International Journal of Cardiology</i> , 2022, 359, 39-45.	1.7	3
206	Aortic Pulsatility Index: A New Haemodynamic Measure with Prognostic Value in Advanced Heart Failure. <i>Cardiac Failure Review</i> , 0, 8, .	3.0	3
207	Optimal Cardiac Resynchronization Therapy Pacing Rate in Non-Ischemic Heart Failure Patients: A Randomized Crossover Pilot Trial. <i>PLoS ONE</i> , 2015, 10, e0138124.	2.5	2
208	Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE). <i>Clinical Transplantation</i> , 2017, 31, e13038.	1.6	2
209	Heart transplantation turns 50 and is going strong. <i>European Journal of Heart Failure</i> , 2017, 19, 1564-1565.	7.1	2
210	When the VEST Does Not Fit. <i>Circulation: Heart Failure</i> , 2018, 11, e005116.	3.9	2
211	Interplay of pump design elements and bleeding predilection—Mechanisms for a forward momentum. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 817-819.	0.6	2
212	Duration of Heart Failure and Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e006022.	3.9	2
213	Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients. <i>ESC Heart Failure</i> , 2020, 7, 567-576.	3.1	2
214	Refining the role of carpal tunnel syndrome in cardiac amyloidosis. <i>European Journal of Heart Failure</i> , 2020, 22, 516-518.	7.1	2
215	Longitudinal shortening of subepicardial myocytes in severe ischaemic cardiomyopathy: insights from gadolinium contrast cardiac magnetic resonance imaging. <i>ESC Heart Failure</i> , 2017, 4, 670-674.	3.1	1
216	Medical and mechanical unloading in advanced heart failure: hope for cardiac recovery?. <i>European Journal of Heart Failure</i> , 2018, 20, 175-177.	7.1	1

#	ARTICLE	IF	CITATIONS
217	The Potential Role of Transcatheter Heart Valve Interventions in Heart Failure Treatment. JACC: Cardiovascular Interventions, 2019, 12, 166-168.	2.9	1
218	First Let's Try Will the Success of New Therapies Paradoxically Challenge Outcomes in Advanced Heart Failure?. Circulation: Heart Failure, 2020, 13, e006610.	3.9	1
219	If it ain't broken, don't fix it (but if it is, make sure you know): aortic valve interventions during left ventricular assist device implantation. European Journal of Heart Failure, 2020, 22, 1888-1890.	7.1	1
220	When Making Your Bed Feels Like Running a Marathon. Circulation: Heart Failure, 2020, 13, e007993.	3.9	1
221	1079. The Risk of Cytomegalovirus (CMV) Infection and Recurrence Among Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2020, 7, S567-S568.	0.9	1
222	Three decades of heart transplantation: experience and long-term outcome. Scandinavian Cardiovascular Journal, 2022, 56, 65-72.	1.2	1
223	Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Current Evidence and Future Perspectives. Basic and Clinical Pharmacology and Toxicology, 2022, , .	2.5	1
224	The Effect of Empagliflozin on Contractile Reserve in Heart Failure: Prespecified Sub-Study of a Randomized, Double-Blind, and Placebo-Controlled Trial. American Heart Journal, 2022, 250, 57-57.	2.7	1
225	Commentary 2. Evidence-based Cardiovascular Medicine, 2005, 9, 219-220.	0.0	0
226	602 Elevation in Liver Transaminase (ALT-flares) in Transplant (TX) Recipients: Risk factors and Consequences. Open Forum Infectious Diseases, 2014, 1, S26-S26.	0.9	0
227	605 Clinically Applied Variation in Replication Kinetics During Episodes of Post-Transplant Cytomegalovirus (CMV) Infections. Open Forum Infectious Diseases, 2014, 1, S27-S27.	0.9	0
228	1168 Use of First Positive Cytomegalovirus (CMV) PCR Determination to Differentiate a Viral Blip From Established CMV Infection in Transplant Recipients. Open Forum Infectious Diseases, 2014, 1, S347-S347.	0.9	0
229	Classification of Death Causes after Transplantation (CLASS): Evaluation of Methodology and Initial Results. Open Forum Infectious Diseases, 2017, 4, S703-S703.	0.9	0
230	Authors' reply re: Subsequent reproductive outcome among women with peripartum cardiomyopathy: a nationwide study. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 1040-1041.	2.3	0
231	1597. Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus (CMV) Infection and Disease in Solid Organ Transplant (SOT) Recipients. Open Forum Infectious Diseases, 2018, 5, S500-S500.	0.9	0
232	1579. Evaluation of MATCH: an Electronic Individual Patient-Focused Management System Aimed at Preventing Cytomegalovirus Disease Following Solid Organ Transplantation. Open Forum Infectious Diseases, 2018, 5, S493-S493.	0.9	0
233	1584. Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next-generation Sequencing. Open Forum Infectious Diseases, 2018, 5, S495-S496.	0.9	0
234	The association of prior carpal tunnel syndrome surgery with adverse cardiovascular outcomes and long-term mortality after aortic valve replacement. IJC Heart and Vasculature, 2021, 33, 100741.	1.1	0

#	ARTICLE	IF	CITATIONS
235	Progressive elimination of adverse events: the key to success for left ventricular assist devices. European Journal of Heart Failure, 2021, 23, 1401-1403.	7.1	0
236	Occult cardiac amyloidosis?. Aging, 2019, 11, 8739-8740.	3.1	0
237	Steroid withdrawal after heart transplantation in adults. Transplant International, 2021, 34, 2469.	1.6	0
238	PRospective Evaluation of natriuretic peptide-based reFERral of patients with chronic heart failure in primary care (PREFER): a real-world study. Open Heart, 2021, 8, e001630.	2.3	0
239	Impact of serial measurements of tricuspid annular plane systolic excursion on mortality and morbidity after heart transplantation. Clinical Transplantation, 2022, , e14662.	1.6	0
240	23. Development and Validation of a Risk Score for Post-transplant Lymphoproliferative Disorders among Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2021, 8, S15-S16.	0.9	0
241	Development and Validation of a Risk Score for Post-Transplant Lymphoproliferative Disorders among Solid Organ Transplant Recipients. Cancers, 2022, 14, 3279.	3.7	0